TREACE MEDICAL CONCEPTS INC (TMCI) Stock Price, Quote, News and Overview
NASDAQ:TMCI - Nasdaq - US89455T1097 - Common Stock - Currency: USD
TMCI Quote, Performance and Key Statistics
5.61
+0.27 (+5.06%)
The current stock price of TMCI is 5.61 USD. In the past month the price decreased by -7.27%. In the past year, price decreased by -3.11%.
TMCI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.52 | 226.06B | ||
| ISRG | INTUITIVE SURGICAL INC | 60.04 | 173.27B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.73 | 157.99B | ||
| SYK | STRYKER CORP | 29.69 | 145.79B | ||
| MDT | MEDTRONIC PLC | 16.3 | 114.85B | ||
| IDXX | IDEXX LABORATORIES INC | 59.89 | 54.91B | ||
| BDX | BECTON DICKINSON AND CO | 12.7 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 31.16 | 46.98B | ||
| RMD | RESMED INC | 30.52 | 42.73B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.16 | 32.34B | ||
| DXCM | DEXCOM INC | 44.85 | 29.90B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.29 | 25.73B |
Related stock screener links
About TMCI
Company Profile
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The firm is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The firm sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
Company Info
TREACE MEDICAL CONCEPTS INC
100 Palmetto Park Place
Ponte Vedra FLORIDA 32081 US
CEO: John T. Treace
Employees: 516
Phone: 19043735940
TREACE MEDICAL CONCEPTS INC / TMCI FAQ
What is the stock price of TREACE MEDICAL CONCEPTS INC today?
The current stock price of TMCI is 5.61 USD. The price increased by 5.06% in the last trading session.
What is the ticker symbol for TREACE MEDICAL CONCEPTS INC stock?
The exchange symbol of TREACE MEDICAL CONCEPTS INC is TMCI and it is listed on the Nasdaq exchange.
On which exchange is TMCI stock listed?
TMCI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TREACE MEDICAL CONCEPTS INC stock?
12 analysts have analysed TMCI and the average price target is 10.42 USD. This implies a price increase of 85.82% is expected in the next year compared to the current price of 5.61. Check the TREACE MEDICAL CONCEPTS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TREACE MEDICAL CONCEPTS INC worth?
TREACE MEDICAL CONCEPTS INC (TMCI) has a market capitalization of 352.87M USD. This makes TMCI a Small Cap stock.
How many employees does TREACE MEDICAL CONCEPTS INC have?
TREACE MEDICAL CONCEPTS INC (TMCI) currently has 516 employees.
What are the support and resistance levels for TREACE MEDICAL CONCEPTS INC (TMCI) stock?
TREACE MEDICAL CONCEPTS INC (TMCI) has a support level at 5.33 and a resistance level at 5.77. Check the full technical report for a detailed analysis of TMCI support and resistance levels.
Is TREACE MEDICAL CONCEPTS INC (TMCI) expected to grow?
The Revenue of TREACE MEDICAL CONCEPTS INC (TMCI) is expected to grow by 9.26% in the next year. Check the estimates tab for more information on the TMCI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TREACE MEDICAL CONCEPTS INC (TMCI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TMCI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TMCI, evaluating the profitability, health, valuation and growth aspects
- TREACE MEDICAL CONCEPTS INC (TMCI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TREACE MEDICAL CONCEPTS INC (TMCI) Sales and EPS estimates to see what analysts future expectations are.
- TREACE MEDICAL CONCEPTS INC (TMCI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TREACE MEDICAL CONCEPTS INC (TMCI) Insider and Institutional Ownership to learn about the owners and their transactions.
- TREACE MEDICAL CONCEPTS INC (TMCI) Stock Chart to make your own analysis
- TREACE MEDICAL CONCEPTS INC (TMCI) Latest news and press-releases to stay up to date.
Does TREACE MEDICAL CONCEPTS INC (TMCI) stock pay dividends?
TMCI does not pay a dividend.
When does TREACE MEDICAL CONCEPTS INC (TMCI) report earnings?
TREACE MEDICAL CONCEPTS INC (TMCI) will report earnings on 2025-08-07, after the market close.
What is the Price/Earnings (PE) ratio of TREACE MEDICAL CONCEPTS INC (TMCI)?
TREACE MEDICAL CONCEPTS INC (TMCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
What is the Short Interest ratio of TREACE MEDICAL CONCEPTS INC (TMCI) stock?
The outstanding short interest for TREACE MEDICAL CONCEPTS INC (TMCI) is 5.88% of its float. Check the ownership tab for more information on the TMCI short interest.
TMCI Technical Analysis
TMCI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TMCI. TMCI has a bad profitability rating. Also its financial health evaluation is rather negative.
TMCI Financial Highlights
Over the last trailing twelve months TMCI reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 9.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.74% | ||
| ROE | -50.3% | ||
| Debt/Equity | 0.51 |
TMCI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to TMCI. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 4.2% and a revenue growth 9.26% for TMCI